Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …

Acute myeloid leukemia (AML) is a hematologic malignancy that most frequently develops in
older adults. Overall, AML is associated with a high mortality although advancements in …

Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in
the United States over the last 4 years, AML remains a major area of unmet medical need …

The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia
(AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment …